This Saturday marks a year this PR:
NuGenerex Immuno-Oncology Spin-Out & Stock Dividend
Generex President & Chief Executive Officer Joe Moscato stated, “NuGenerex
Immuno-Oncology is being established to not only to advance the NuGenerex
Immuno-Oncology core technology, but also to expand the Company’s portfolio in
the field of immunotherapy and personalized medicine through partnerships and
acquisitions. As part of our strategy, we are exploring opportunities to spin-out
NuGenerex Immuno-Oncology as a separate DTC-eligible SEC registered
company. Mr. Moscato stated that following the spin-out, NuGenerex ImmunoOncology is expected to seek to list its common stock on a national stock
exchange. "The spin-out of NuGenerex Immuno-Oncology into a separate, publicly
Page 2 of 3
traded entity has been the focus of the Generex strategic development plan in
cancer drug development," Mr. Moscato indicated. "The Ii-Key technology has
been underappreciated for too long, as we have advanced the immunotherapy field
with the largest breast cancer vaccine study ever conducted, and now the results
of that trial have led to an exciting combination Phase II trial with AE37 plus
Ketruda in triple negative breast cancer. We believe this spin-out will help to
unlock the true value of the Ii-Key technology for our stockholders as it creates a
pure play in immunotherapy, which will foster investment and collaboration.”
The spin-out will be accomplished by the issuance of one or more dividends of
NuGenerex Immuno-Oncology stock to Generex stockholders. The record dates
in respect of such dividends are yet to be determined and will be announced in
due course. The stock dividends will enable Generex stockholders to directly
participate in the promising future of NuGenerex Immuno-Oncology as well as
create a large shareholder base with the potential for substantial liquidity on an
immediate basis. That liquidity will be further enhanced should NuGenerex
Immuno-Oncology be successful in attaining a national stock exchange listing, and
should provide NuGenerex Immuno-Oncology with ready access to the capital
markets to finance its on-going clinical and regulatory initiatives.
Following the issuance of stock dividends, Generex expects to retain a controlling
interest in NuGenerex Immuno-Oncology, but the exact proportion of the shares
to be held by Generex has not yet been determined.
Subject to market conditions and the satisfaction of regul
NuGenerex Immuno-Oncology Spin-Out & Stock Dividend
Generex President & Chief Executive Officer Joe Moscato stated, “NuGenerex
Immuno-Oncology is being established to not only to advance the NuGenerex
Immuno-Oncology core technology, but also to expand the Company’s portfolio in
the field of immunotherapy and personalized medicine through partnerships and
acquisitions. As part of our strategy, we are exploring opportunities to spin-out
NuGenerex Immuno-Oncology as a separate DTC-eligible SEC registered
company. Mr. Moscato stated that following the spin-out, NuGenerex ImmunoOncology is expected to seek to list its common stock on a national stock
exchange. "The spin-out of NuGenerex Immuno-Oncology into a separate, publicly
Page 2 of 3
traded entity has been the focus of the Generex strategic development plan in
cancer drug development," Mr. Moscato indicated. "The Ii-Key technology has
been underappreciated for too long, as we have advanced the immunotherapy field
with the largest breast cancer vaccine study ever conducted, and now the results
of that trial have led to an exciting combination Phase II trial with AE37 plus
Ketruda in triple negative breast cancer. We believe this spin-out will help to
unlock the true value of the Ii-Key technology for our stockholders as it creates a
pure play in immunotherapy, which will foster investment and collaboration.”
The spin-out will be accomplished by the issuance of one or more dividends of
NuGenerex Immuno-Oncology stock to Generex stockholders. The record dates
in respect of such dividends are yet to be determined and will be announced in
due course. The stock dividends will enable Generex stockholders to directly
participate in the promising future of NuGenerex Immuno-Oncology as well as
create a large shareholder base with the potential for substantial liquidity on an
immediate basis. That liquidity will be further enhanced should NuGenerex
Immuno-Oncology be successful in attaining a national stock exchange listing, and
should provide NuGenerex Immuno-Oncology with ready access to the capital
markets to finance its on-going clinical and regulatory initiatives.
Following the issuance of stock dividends, Generex expects to retain a controlling
interest in NuGenerex Immuno-Oncology, but the exact proportion of the shares
to be held by Generex has not yet been determined.
Subject to market conditions and the satisfaction of regul
